The Future of Genomic Medicine Involves the Maintenance of Sirtuin 1 in Global Populations

Abstract

Genomic healthcare now requires the need for the critical assessment of novel molecular biological discoveries that may identify anti-aging genes and transcription factors that are defective in non alcoholic fatty liver disease (NAFLD), obesity, diabetes, cardiovascular disease and neurodegenerative diseases. It is estimated that 30% of the global community will be at risk for NAFLD and the future of genomics in medicine may require nutrigenomics in shaping medicine with fundamental shifts in how we define the nutritional treatment of global chronic disease. The Sirtuin 1 (Sirt 1) gene has now been identified as the gene to be defective and linked to genetic diseases, NAFLD, diabetes and neurodegenerative diseases. Bacterial lipopolysaccharide (LPS) may induce various chronic diseases and may act as a competitive inhibitor to Sirt 1 with glucose and cholesterol toxicity to various cells and tissues. Nutritional diets are required to activate Sirt 1 and improve drug response to cells with increased hepatic drug metabolism important to prevent drug induced toxicity with relevance to the global chronic disease epidemic.